title: Long-term results of oxybutynin treatment for palmar hyperhidrosis.
abstract: OBJECTIVE
  Palmar hyperhidrosis (PH) is a common illness that significantly impacts Quality of Life (QOL). Oxybutynin offers excellent short-term results, but long-term follow-up results are limited. We evaluated its effectiveness in a large group of patients who did not have surgery and who had at least 6 months of follow-up.
  
  
  METHODS
  Between September 2007 and September 2013, 570 consecutive patients were enrolled in our institutional protocol regarding the "pharmacological-first" treatment of primary PH with oxybutynin. Fifty-nine were lost to follow-up, and the data were available for 511 patients treated for at least 6 weeks. Data recorded at the start of the protocol, 6 weeks after beginning treatment, and during patients' final visits were analyzed.
  
  
  RESULTS
  112 patients (21.9 %) did not improve and were referred for surgery (sympathectomy). Eight (1.56 %) developed significant side effects (e.g., dry mouth) and discontinued therapy. Thirty (5.9 %) preferred surgery over pharmacological treatment. 111 have not yet received treatment for 6 months. The 246 patients with more than 6 months of follow-up (median 16 months, range 6-72) were analyzed, as follows: 90.2 % experienced moderate or great improvement in their PH; 90.34 % experienced improvement at other sites of hyperhidrosis following a median of 16 months.
  
  
  CONCLUSIONS
  Among patients with good initial responses to oxybutynin, more than 90 % experienced moderate or great improvement in their palmar sweating, as well as in their hyperhidrosis in other sites, after 6 months. The results were particularly favorable in those patients with BMI <25 kg/m(2), and in those who noted an improved QOL after 6 weeks.
authors.affiliation: Hospital Israelita Albert Einstein, Av. Albert Einstein, 627 Room 423, A1 Building São Paulo, São Paulo, 05652-000, Brazil.
authors.forename: Nelson
authors.initials: N
authors.lastname: Wolosker
authors.forename: Marcelo Passos
authors.initials: MP
authors.lastname: Teivelis
authors.forename: Mariana
authors.initials: M
authors.lastname: Krutman
authors.forename: Rafael P
authors.initials: RP
authors.lastname: de Paula
authors.forename: José R M
authors.initials: JR
authors.lastname: de Campos
authors.forename: Paulo
authors.initials: P
authors.lastname: Kauffman
authors.forename: Pedro
authors.initials: P
authors.lastname: Puech-Leão
mesh_terms: D000293:Adolescent; D000328:Adult; D015992:Body Mass Index; D002648:Child; D002675:Child, Preschool; D005260:Female; D006225:Hand; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy*; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D018721:Muscarinic Agonists / Q000627:therapeutic use*; D011788:Quality of Life; D055815:Young Adult
chemical_list: D008333:Mandelic Acids; D018721:Muscarinic Agonists; C005419:oxybutynin